↓ Skip to main content

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study

Overview of attention for article published in Diabetes Therapy, October 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
24 Mendeley
Title
Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
Published in
Diabetes Therapy, October 2014
DOI 10.1007/s13300-014-0086-7
Pubmed ID
Authors

Kohei Kaku, Hiroshi Maegawa, Yukio Tanizawa, Arihiro Kiyosue, Yumiko Ide, Takuto Tokudome, Yuji Hoshino, Jisin Yang, Anna Maria Langkilde

Abstract

Dapagliflozin is a selective sodium glucose co-transporter 2 inhibitor that improves glycemic control and reduces body weight and systolic blood pressure in patients with type 2 diabetes mellitus (T2DM). Dapagliflozin is effective and well tolerated over 12-24 weeks in Japanese patients with T2DM. In this study, the safety and efficacy of dapagliflozin administered as monotherapy and combination therapy were assessed over 52 weeks in Japanese patients with T2DM.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 21%
Student > Master 5 21%
Unspecified 4 17%
Researcher 4 17%
Other 3 13%
Other 3 13%
Readers by discipline Count As %
Medicine and Dentistry 11 46%
Pharmacology, Toxicology and Pharmaceutical Science 5 21%
Unspecified 4 17%
Nursing and Health Professions 2 8%
Engineering 2 8%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2014.
All research outputs
#7,176,245
of 12,434,754 outputs
Outputs from Diabetes Therapy
#151
of 415 outputs
Outputs of similar age
#101,124
of 231,985 outputs
Outputs of similar age from Diabetes Therapy
#3
of 17 outputs
Altmetric has tracked 12,434,754 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 415 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 231,985 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.